Drug Trial Radar · NCT07059403
A Study of SN2001 Dose, Safety & Immunogenicity in Healthy Adults
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Aug 19, 2025
Primary completion
Apr 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- Chimivac INCIndustry
- Sponsor type
- Industry
- First posted
- Jul 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, multiple-ascending-dose study of SN2001 in healthy adult subjects. The study is designed to evaluate the safety, tolerability and immunogenicity of SN2001.
Conditions
- Chronic Hepatitis B Infection
Interventions
SN2001Biological
100 µg, for subcutaneous (SC) injection
SN2001Biological
200 µg, for subcutaneous (SC) injection
SN2001Biological
300 µg, for subcutaneous (SC) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs)Time frame: from the time of the first study injection through 48 Weeks after the final study injection
- Number of subjects with clinically significant abnormalities in vital signs graded by 2007 FDA Guidance.Time frame: from the time of the first study injection through 48 Weeks after the final study injection
- Number of subjects with clinically significant abnormalities in physical examination graded by 2007 FDA Guidance.Time frame: from the time of the first study injection through 48 Weeks after the final study injection
- Number of subjects with clinically significant abnormalities in 12-lead electrocardiogram (ECG) graded by 2007 FDA Guidance.Time frame: from the time of the first study injection through 48 Weeks after the final study injection
- Number of subjects with clinically significant abnormalities in laboratory parameters graded by 2007 FDA Guidance.Time frame: from the time of the first study injection through 48 Weeks after the final study injection
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Q-Pharm Pty Ltd.
Herston, Queensland, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.